
    
      This is a Phase 1, open-label, assessor-blind, parallel-group study to evaluate the PK and
      tolerability of a single subcutaneous dose of 300 milligram (mg) tralokinumab when delivered
      as a 2 milliliters (mL) injection at different flow rates to healthy adult volunteers.
    
  